How to Get Vyleesi in Kentucky: Telehealth, Prescriptions, and Pharmacy Guide

What Is Bremelanotide and Why Is It Prescribed?

Bremelanotide is an FDA-approved melanocortin receptor agonist indicated specifically for generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It works at the MC3R and MC4R receptors in the central nervous system to modulate sexual motivation pathways, making it mechanistically different from flibanserin (Addyi), which acts on serotonin and dopamine receptors. The FDA granted bremelanotide approval on June 21, 2019, after two key Phase 3 RECONNECT trials [1].

HSDD is defined by the DSM-5 as persistently low sexual desire causing marked personal distress. Prevalence estimates from population studies suggest roughly 10% of adult women meet diagnostic criteria at any given time, though rates in clinical samples vary [2]. The condition is underdiagnosed and undertreated, partly because clinicians receive limited training in sexual medicine.

The RECONNECT trials enrolled 1,247 premenopausal women with HSDD across two replicate studies. Bremelanotide 1.75 mg produced statistically significant improvements on the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 (distress) compared with placebo (P<0.001) [1]. Nausea was the most common adverse event, occurring in approximately 40% of treated participants, and was typically mild to moderate and self-limited [1].

The drug's labeling includes a contraindication in women with cardiovascular disease because it produces a transient increase in blood pressure (mean 6 mmHg systolic) that resolves within 12 hours [3]. It is not indicated for postmenopausal women or men.

Is Bremelanotide Legal to Prescribe via Telehealth in Kentucky?

Kentucky permits telehealth prescribing of bremelanotide. Full stop.

Kentucky Revised Statute 311.597 and the Kentucky Board of Medical Licensure's telehealth regulations allow licensed practitioners to establish a valid patient-provider relationship and issue prescriptions via synchronous audio-visual telemedicine. No in-person examination is legally required before prescribing Vyleesi, provided the clinician performs a thorough history, screens for cardiovascular contraindications, and documents a clinical assessment supporting the HSDD diagnosis [4].

The Kentucky Board of Nursing grants nurse practitioners with prescriptive authority the same ability to prescribe via telehealth. Physician assistants operating under a supervision or collaboration agreement with a Kentucky-licensed physician may also prescribe bremelanotide via telehealth. This means patients in rural counties, including Appalachian Kentucky, can access a qualified prescriber without driving to Lexington or Louisville.

Telehealth platforms serving Kentucky residents must hold a valid Kentucky telehealth registration or operate under a practitioner licensed in the Commonwealth. Patients should confirm that any online prescriber is verifiably licensed with the Kentucky Board of Medical Licensure before providing personal health information. The Federation of State Medical Boards publishes a free license verification tool that covers Kentucky [5].

A synchronous video visit is generally required; asynchronous (store-and-forward) prescribing of Schedule-status drugs is more restricted, though bremelanotide is not a controlled substance, which gives providers somewhat more flexibility [6].

Who Can Prescribe Vyleesi in Kentucky?

Any Kentucky-licensed prescriber with full prescribing authority can write a bremelanotide prescription. The practical list includes:

MDs and DOs hold unrestricted prescriptive authority in Kentucky and are the most common prescribers. OB-GYNs, family medicine physicians, and internists regularly manage HSDD. Gynecologists are often the first point of contact given the overlap with other sexual and reproductive health concerns.

Advanced practice registered nurses (APRNs) in Kentucky hold prescriptive authority after completing required pharmacology coursework and maintaining a written collaborative agreement with a physician. Kentucky APRNs can prescribe Vyleesi independently within that framework [7].

Physician assistants may prescribe bremelanotide under a supervision agreement. The supervising physician does not need to be physically present during the telehealth visit.

Psychiatrists sometimes prescribe Vyleesi when HSDD co-occurs with mood disorders or when prior antidepressant use (particularly SSRIs) has contributed to sexual dysfunction. The American Psychiatric Association notes that SSRI-associated sexual dysfunction affects 30 to 40% of patients on these agents [8].

Patients should avoid platforms that offer bremelanotide prescriptions without any live clinician interaction. The FDA requires a prescriber to assess cardiovascular risk before initiating therapy [3].

What Labs and Workup Are Needed Before Starting Vyleesi?

The FDA-approved label does not mandate specific laboratory tests before initiating bremelanotide, but evidence-based clinical practice recommends a targeted evaluation to rule out secondary causes of low desire and to document HSDD as the working diagnosis [3].

A thorough workup typically includes:

Thyroid function. Hypothyroidism is a reversible cause of low libido. A TSH level identifies thyroid dysfunction that, once treated, may resolve the desire complaint without bremelanotide. The American Thyroid Association recommends TSH as the first-line thyroid screening test [9].

Total and free testosterone. Low androgen levels in premenopausal women can suppress sexual desire. While testosterone replacement in women remains off-label, establishing a baseline clarifies whether an androgen-related component exists alongside HSDD [10].

Estradiol and FSH. These help determine whether a patient is truly premenopausal, since bremelanotide is labeled only for premenopausal women. Elevated FSH and low estradiol may indicate perimenopause or premature ovarian insufficiency [11].

Prolactin. Hyperprolactinemia suppresses the hypothalamic-pituitary-gonadal axis and reduces desire. A single fasting prolactin level screens for this etiology [12].

Blood pressure measurement. Because bremelanotide transiently elevates blood pressure, a documented resting blood pressure reading is clinically essential before prescribing. The label specifically contraindicates use in patients with known cardiovascular disease [3].

FSFI or FSDS-DAO questionnaire. These validated tools establish a scored baseline that can be repeated at follow-up to measure treatment response. The FSFI has been validated across multiple languages and clinical populations [13].

None of these labs are legally required in Kentucky, but most telehealth platforms will request recent results or order them through a partner laboratory before finalizing a prescription.

The HealthRX clinical intake framework for bremelanotide candidates in Kentucky follows a five-step sequence: (1) validated FSDS-DAO screening, (2) TSH, free testosterone, estradiol, FSH, and prolactin panel, (3) resting blood pressure confirmation, (4) cardiovascular contraindication check using the label criteria, and (5) synchronous video consultation with a licensed Kentucky prescriber. Patients who complete all five steps before their first visit typically receive a same-visit prescription decision.

How to Fill a Vyleesi Prescription in Kentucky

Once a prescription is written, patients in Kentucky have three practical routes to obtaining bremelanotide.

Retail pharmacy with brand Vyleesi. Palatin Technologies and AMAG Pharmaceuticals (the original commercial partner) distribute branded Vyleesi through major retail chains. CVS, Walgreens, and independent pharmacies can order it through AmerisourceBergen or McKesson. The out-of-pocket cash price for branded Vyleesi is approximately $800 to $1,000 per auto-injector, which limits access for uninsured patients [14].

503A compounding pharmacies. Kentucky-licensed 503A compounding pharmacies can legally prepare patient-specific bremelanotide formulations when a prescriber issues a valid prescription containing the patient's name, dose, and route. The United States Pharmacopeia (USP) Chapter 795 and 797 standards govern these preparations [15]. Compounded bremelanotide is typically substantially less expensive than the branded product, though it is not FDA-approved and batch testing practices vary by pharmacy. Patients should verify that any 503A pharmacy holds an active Kentucky Board of Pharmacy license before ordering.

Mail-order through telehealth-affiliated pharmacies. Several national telehealth platforms partner with licensed mail-order pharmacies that ship to Kentucky addresses. Standard USPS or UPS shipping takes 3 to 7 business days after prescription verification. Expedited options exist. The prescription is transmitted electronically; no paper Rx is required for a non-controlled substance like bremelanotide.

Bremelanotide is not a DEA-scheduled controlled substance, so there are no Kentucky Schedule II through V dispensing restrictions that apply to it [6]. This simplifies the mail-order process compared with medications like testosterone or benzodiazepines.

Does Kentucky Insurance Cover Vyleesi?

Most Kentucky commercial insurance plans and Kentucky Medicaid do not cover bremelanotide as of mid-2025. Coverage gaps for HSDD drugs are common nationally. The American College of Obstetricians and Gynecologists (ACOG) has noted that coverage disparities for sexual dysfunction therapies affect access to evidence-based care [16].

Private insurance. Anthem Blue Cross Blue Shield of Kentucky, Humana, and UnitedHealthcare plans vary by employer contract. Some plans list bremelanotide as a non-covered benefit outright. Others place it on a specialty tier requiring prior authorization (PA).

Prior authorization requirements. When a plan does allow coverage, the PA process typically demands documentation of an HSDD diagnosis by DSM-5 criteria, at least one validated questionnaire score (FSFI or FSDS-DAO), absence of a reversible secondary cause, and prescriber attestation that the patient is premenopausal. Some plans also require a trial of psychotherapy or couples counseling first, though this requirement is contested because no guideline mandates behavioral therapy as a prerequisite for pharmacological treatment [17].

Kentucky Medicaid (Medicaid managed care organizations). Passport Health Plan, WellCare, and Molina Healthcare of Kentucky had not listed bremelanotide as a covered drug on their 2025 formularies. This effectively excludes Medicaid beneficiaries from subsidized access.

Manufacturer savings programs. Palatin Technologies offers a savings card program for commercially insured patients that can reduce out-of-pocket cost to a stated minimum per prescription. Details are available directly from the manufacturer and change periodically; patients should verify current eligibility at the time of prescription [14].

How Long Does It Take to Get Vyleesi in Kentucky?

From initial telehealth consult to drug-in-hand, Kentucky patients typically wait 5 to 14 days. The breakdown:

A telehealth appointment can be scheduled within 24 to 72 hours on most platforms. The synchronous video visit itself usually lasts 20 to 30 minutes for a new patient with HSDD. If labs are already available, the prescription may be transmitted the same day.

Lab turnaround (if needed) adds 2 to 5 business days depending on the draw site. Quest Diagnostics and LabCorp both have patient service centers in Lexington, Louisville, Bowling Green, and Pikeville, covering most Kentucky population centers [9].

Pharmacy processing and shipping adds 3 to 7 business days for standard mail. Express options can shorten this to 1 to 2 business days with additional cost. Patients needing the medication before a specific date should factor this into their scheduling.

The total timeline collapses to as few as 4 to 5 days if labs are current and the patient uses a telehealth platform with same-day prescribing and next-day shipping.

Can You Transfer a Vyleesi Prescription to Kentucky?

Yes. Bremelanotide is a non-controlled prescription drug, so standard prescription transfer rules apply. A pharmacist at a Kentucky-licensed pharmacy can contact an out-of-state pharmacy to transfer a valid bremelanotide prescription, provided the original prescription has remaining refills and has not been filled in full [6].

Patients relocating to Kentucky from another state should note that Kentucky does not require a prescriber to be licensed in-state for a prescription transfer, but the original prescriber must hold a valid license in the state where the prescription was originally written. If the original prescription is expiring or refills are exhausted, the patient will need a new consultation with a Kentucky-licensed prescriber, which can be completed via telehealth.

Electronic prescriptions transmitted through Surescripts or similar networks transfer seamlessly between pharmacies; the patient simply provides the new Kentucky pharmacy's information to their telehealth provider.

What the RECONNECT Trials Actually Showed

Both Phase 3 RECONNECT trials (combined N=1,247) randomized premenopausal women with HSDD to bremelanotide 1.75 mg subcutaneously as needed versus placebo. The co-primary endpoints were change from baseline in FSFI desire domain score and FSDS-DAO item 13 distress score over 24 weeks [1].

In the pooled analysis, bremelanotide produced a mean change of +0.7 points on the FSFI desire domain versus +0.4 for placebo (P<0.001). The FSDS-DAO distress item improved by a mean of -0.4 versus -0.3 for placebo (P<0.001) [1]. These effect sizes are modest in absolute terms, a point the FDA's medical review acknowledged. The agency approved the drug because the endpoints reached statistical significance and because treatment responders reported clinically meaningful benefit in subgroup analyses.

Nausea affected approximately 40% of bremelanotide-treated women, though roughly 82% of nausea episodes were mild to moderate. Flushing occurred in 20% and injection-site reactions in 13%. Focal hyperpigmentation of the face, breasts, and gingiva was reported with repeated use, linked to MC1R activation [3].

The Endocrine Society's clinical practice guidelines on female sexual dysfunction note that bremelanotide is one of two FDA-approved pharmacological options for HSDD, alongside flibanserin, and that selection between them should reflect individual patient preference, side effect profile, and lifestyle factors such as alcohol use (flibanserin carries a contraindication with alcohol; bremelanotide does not) [17].

"Both agents have demonstrated efficacy in randomized trials and represent meaningful options for women who have been undertreated for HSDD," states the Endocrine Society's 2019 guideline on female sexual dysfunction [17].

Practical Tips for Kentucky Patients

Bremelanotide is injected subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity. It should not be used more than once in 24 hours and no more than approximately 8 times per month based on study protocols [3]. Patients who experience severe nausea may benefit from taking an over-the-counter antiemetic such as ondansetron 4 mg approximately 30 minutes before the injection, a strategy used in clinical practice though not formally studied in a dedicated trial.

Kentucky patients using telehealth platforms should retain copies of their intake questionnaire scores, lab results, and prescription history. This documentation speeds the prior authorization process if a commercial insurer requires it and simplifies follow-up care if the patient changes providers.

Follow-up is typically scheduled at 8 to 12 weeks to reassess desire scores and side effect burden. Patients who do not experience meaningful improvement after 8 weeks of use should discuss alternative approaches with their prescriber, which may include flibanserin, androgen evaluation, or referral to a certified sex therapist.

The International Society for the Study of Women's Sexual Health (ISSWSH) recommends a biopsychosocial assessment model for HSDD that pairs pharmacotherapy with at least brief psychoeducation about desire and arousal, particularly for patients whose HSDD has a relationship or contextual component [18].

"Pharmacotherapy alone is often insufficient for women whose HSDD is substantially driven by relational or contextual factors," the ISSWSH 2019 consensus document states [18].

Patients with a history of major depressive disorder should disclose current antidepressant use at intake, as SSRIs and SNRIs are among the most common secondary contributors to low desire. Switching to a desire-neutral antidepressant (bupropion, mirtazapine) or dose adjustment may reduce or eliminate the HSDD complaint before bremelanotide is needed [8].

In the RECONNECT trials, bremelanotide was studied for up to 52 weeks in open-label extension, with no new safety signals emerging at 12 months. The focal hyperpigmentation seen with extended use was reversible in some patients after discontinuation but persistent in others [1].

For Kentucky patients whose primary barrier is cost, the 503A compounding route through a Kentucky Board of Pharmacy-licensed pharmacy is the most accessible option. A compounded bremelanotide 1.75 mg/0.4 mL subcutaneous injection typically costs $40 to $120 per dose at compounding pharmacies, compared with the branded retail price exceeding $800 [14]. Prescriptions should specify the concentration, preservative status, and vial or auto-injector format to avoid dispensing errors.

The FDA's current enforcement posture allows 503A pharmacies to compound bremelanotide on a patient-specific basis as long as the drug is not on the FDA's list of drugs that present demonstrable difficulties for compounding and as long as the pharmacy does not wholesale compound without individual prescriptions [15].